Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | AOC3 | Q16853 | 6/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82461 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL2438955 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL2763479 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL3802461 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL82462 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL17514076 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL14959742 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL1131702 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL8120379 | 0.89 | DPP4 (0.52) | DPP4KDM4EADRA2AADRA2CLMNA | |
| Alcohol SCHEMBL8325116 | 0.89 | KDM4E (0.57) | DPP4KDM4EADRA2AADRA2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 482 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025104679-A1 | PROCESSES FOR MAKING INTERMEDIATES FOR ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-05-22 | — | — | WO | claimed |
| EP-3694864-B1 | BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF | QPEX BIOPHARMA INC (US) | 2025-03-05 | — | — | EP | claimed |
| CN-117447462-A | Chiral triazole-oxazoline compound and preparation method and application thereof | 吉林大学 | 2024-01-26 | — | — | CN | claimed |
| CN-117399070-A | Chiral metal synergistic catalytic system containing chelating ligand and application of chiral metal synergistic catalytic system in asymmetric synthesis of bedaquiline | 上海交通大学 | 2024-01-16 | — | — | CN | claimed |
| US-20230416252-A1 | PROCESS TOWARD THE MANUFACTURE OF (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}- 1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B][1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE | JANSSEN PHARMACEUTICA NV (BE) | 2023-12-28 | — | — | US | claimed |
| CN-117120418-A | Process for the preparation of compound (I) | 百时美施贵宝公司 | 2023-11-24 | — | — | CN | claimed |
| CN-116899502-A | Method for preparing bedaquiline by low-temperature continuous flow and prepared product | 上海交通大学 | 2023-10-20 | — | — | CN | claimed |
| CN-116685322-A | Method for synthesizing substituted pyridone-pyridyl compounds | 阿克拉瑞斯治疗股份有限公司 | 2023-09-01 | — | — | CN | claimed |
| EP-4225757-A1 | A PROCESS TOWARD THE MANUFACTURE OF (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}-1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B] [1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE | Bristol-Myers Squibb Company (US) | 2023-08-16 | — | — | EP | claimed |
| CN-115465853-B | Orange light carbon dot based on citric acid and chiral 2-amino-1, 2-diphenyl ethanol and preparation method and application thereof | 西华大学 | 2023-06-20 | — | — | CN | claimed |
| CN-1087348-C | Pacemate separation of primary and secondary heteroatom-substituted amine by enzyme-catalysed acylation | BASF AG (DE) | 2002-07-10 | — | — | CN | claimed |
| US-20020058788-A1 | Facile deprotection of Fmoc protected amino groups | DISCOVERY PARTNERS INTERNATIONAL, INC. | 2002-05-16 | — | — | US | claimed |
| EP-0844230-A2 | Optical resolution method of (plus, minus)-3,4-dihydroxybutanoic acid | KURARAY CO., LTD. (JP) | 1998-05-27 | — | — | EP | claimed |
| EP-0708764-A1 | ENANTHIOSELECTIVE PREPARATION OF THIAZOLE DERIVATIVES | PFIZER INC. (US) | 1996-05-01 | — | — | EP | claimed |
| EP-0485069-B1 | Process for producing optically active amines | SUMITOMO CHEMICAL CO (JP) | 1995-02-15 | — | — | EP | claimed |
| WO-1995002585-A1 | ENANTHIOSELECTIVE PREPARATION OF THIAZOLE DERIVATIVES | PFIZER INC. (US) | 1995-01-26 | — | — | WO | claimed |
| US-5200561-A | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-04-06 | — | — | US | claimed |
| EP-0485069-A1 | Process for producing optically active amines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-05-13 | — | — | EP | claimed |
| EP-0085023-A1 | Process for the separation of enantiomers by partition between liquid phases | CIBA-GEIGY AG (CH) | 1983-08-03 | — | — | EP | claimed |
| US-3988456-A | ANALGESICS, ANTITUSSIVE | DAINIPPON PHARMACEUTICAL CO., LTD. (JA) | 1976-10-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058788-A1 | Facile deprotection of Fmoc protected amino groups | DNPEP, LNPEP, NPEPPS | DPP4 315/4885KDM4E 1101/4885ADRA2A 4540/4885 |
| US-20230416252-A1 | PROCESS TOWARD THE MANUFACTURE OF (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}- 1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B][1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE | CYP1B1, AZI2, TET1 | DPP4 370/4885KDM4E 689/4885ADRA2A 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.